Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bio Green Med Solution, Inc.CYCC · Entity 8225 | Director | June 15, 2021 | June 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bio Green Med Solution, Inc.
Report date June 15, 2021 · Filed June 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,374 |
Reported balance
After 2021-06-15 transaction · row 1
1 source rowRow 1 · 2021-06-15 · Grant · Acquired 2,374 · Balance 2,374 F1: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.69 · Expires 2031-06-15 | Direct | 4,748 |
Reported balance
After 2021-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-15 · Grant · Acquired 4,748 · Balance 4,748 F2: These options were granted to Mr. Hradsky for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022.
F2: These options were granted to Mr. Hradsky for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2021 Filed Jun 17, 2021 20:09 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 4,748 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001104659-21-082605 · tm2119990d7_4.xml · derivative · entry 2 Hradsky Gregory T. · CIK 0001439092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,748 Underlying: Common Stock · 4,748 shares Expires 2031-06-15 F2 · price: These options were granted to Mr. Hradsky for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:09 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantCommon Stock | 2,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082605 · tm2119990d7_4.xml · nonDerivative · entry 1 Hradsky Gregory T. · CIK 0001439092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,374 F1 · shares: The reporting person received an award of 2,374 restricted stock units on June 15, 2021, which shall vest in full on June 15, 2022. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 22:50 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 5,200 | $0.00 Strike: $4.70 | $0.00 |
DisclosureSEC source: 0001104659-20-078129 · tm2023597-6_4.xml · derivative · entry 1 Hradsky Gregory T. · CIK 0001439092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-06-25 F1 · price: These options were granted to Mr. Hradsky for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:40 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001144204-19-029260 · tv522827_form4.xml · derivative · entry 1 Hradsky Gregory T. · CIK 0001439092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2029-05-29 F1 · price: These options were granted to Mr. Hradsky for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 21:30 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 8,576 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001144204-18-032712 · tv495788_form4.xml · derivative · entry 1 Hradsky Gregory T. · CIK 0001439092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,576 Underlying: Common Stock · 8,576 shares Expires 2028-05-31 F1 · price: These options were granted to Mr. Hradsky for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 21:06 UTC | Bio Green Med Solution, Inc. CYCC · Entity 8225 | GrantStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001571049-17-005586 · t1701732_x4-f4.xml · derivative · entry 1 Hradsky Gregory T. · CIK 0001439092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-05-30 F1 · price: These options were granted to Mr. Hradsky for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.